Medincell SA
PAR:MEDCL

Watchlist Manager
Medincell SA Logo
Medincell SA
PAR:MEDCL
Watchlist
Price: 16.76 EUR Market Closed
Market Cap: 490.1m EUR
Have any thoughts about
Medincell SA?
Write Note

Medincell SA
Income from Continuing Operations

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Medincell SA
Income from Continuing Operations Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Income from Continuing Operations CAGR 3Y CAGR 5Y CAGR 10Y
Medincell SA
PAR:MEDCL
Income from Continuing Operations
-€25m
CAGR 3-Years
-10%
CAGR 5-Years
-5%
CAGR 10-Years
N/A
Sanofi SA
PAR:SAN
Income from Continuing Operations
€7.1B
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Ipsen SA
PAR:IPN
Income from Continuing Operations
€661.9m
CAGR 3-Years
2%
CAGR 5-Years
10%
CAGR 10-Years
16%
Vetoquinol SA
PAR:VETO
Income from Continuing Operations
€47.1m
CAGR 3-Years
5%
CAGR 5-Years
7%
CAGR 10-Years
7%
Virbac SA
PAR:VIRP
Income from Continuing Operations
€480m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Boiron SA
PAR:BOI
Income from Continuing Operations
€22.4m
CAGR 3-Years
8%
CAGR 5-Years
-9%
CAGR 10-Years
-12%
No Stocks Found

Medincell SA
Glance View

Market Cap
487.2m EUR
Industry
Pharmaceuticals

MedinCell SA is a pharmaceutical company, which engages in the development of injectable products in therapeutic areas. The company is headquartered in Jacou, Occitanie and currently employs 150 full-time employees. The company went IPO on 2018-10-08. The firm is focused on the development of therapeutic solutions with worldwide access. The firm works on both for-profit and non-profit projects, in collaboration with partners ranging from pharmaceutical corporations to physicians, from biotechnology firms to academics and foundations. Its range of products consists of three products in development phase: mdc-IRM, a subcutaneous injection in phase III clinical study for the treatment of schizophrenia; mdc-CWM, an intra-articular injection in phase II clinical study for the treatment of post-surgical pain and inflammation; mdc-TJK, a subcutaneous injection for the treatment of schizophrenia, as well as a number of other products that are in the research phase, such as mdc-WWM, which is a subcutaneous injection for contraception, and mdc-ELK, a subcutaneous injection for the treatment of depression, among others.

MEDCL Intrinsic Value
21.71 EUR
Undervaluation 23%
Intrinsic Value
Price

See Also

What is Medincell SA's Income from Continuing Operations?
Income from Continuing Operations
-25m EUR

Based on the financial report for Mar 31, 2024, Medincell SA's Income from Continuing Operations amounts to -25m EUR.

What is Medincell SA's Income from Continuing Operations growth rate?
Income from Continuing Operations CAGR 5Y
-5%

Over the last year, the Income from Continuing Operations growth was 22%. The average annual Income from Continuing Operations growth rates for Medincell SA have been -10% over the past three years , -5% over the past five years .

Back to Top